In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

@article{Waites2003InVS,
  title={In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.},
  author={Ken B. Waites and Donna M. Crabb and Xue Bing and Lynn B. Duffy},
  journal={Antimicrobial agents and chemotherapy},
  year={2003},
  volume={47 1},
  pages={161-5}
}
The in vitro susceptibilities to garenoxacin (BMS-284756), an investigational des-fluoroquinolone, and eight other agents were determined for 63 Mycoplasma pneumoniae, 45 Mycoplasma hominis, 15 Mycoplasma fermentans, and 68 Ureaplasma sp. isolates. Garenoxacin was the most active quinolone, inhibiting all isolates at <or=1 microg/ml. The garenoxacin MIC at which 90% of isolates are inhibited (MIC(90)s; <or=0.008 microg/ml) was at least 4-fold less than those of moxifloxacin and clindamycin, 8… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
The garenoxacin MIC at which 90% of isolates are inhibited ( MIC(90)s ; < or=0.008 microg / ml ) was at least 4-fold less than those of moxifloxacin and clindamycin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin for M. pneumoniae .
For Ureaplasma spp . , the garenoxacin MIC(90 ) ( 0.25 microg / ml ) was equivalent to those of moxifloxacin and doxycycline , 4-fold less than those of levofloxacin and sparfloxacin , 8-fold less than that of azithromycin , and 32-fold less than that of ciprofloxacin .
For M. hominis , the garenoxacin MIC(90 ) ( < or=0.008 microg / ml ) was 4-fold less than those of clindamycin and moxifloxacin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin .
For M. hominis , the garenoxacin MIC(90 ) ( < or=0.008 microg / ml ) was 4-fold less than those of clindamycin and moxifloxacin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin .
The garenoxacin MIC at which 90% of isolates are inhibited ( MIC(90)s ; < or=0.008 microg / ml ) was at least 4-fold less than those of moxifloxacin and clindamycin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin for M. pneumoniae .
For Ureaplasma spp . , the garenoxacin MIC(90 ) ( 0.25 microg / ml ) was equivalent to those of moxifloxacin and doxycycline , 4-fold less than those of levofloxacin and sparfloxacin , 8-fold less than that of azithromycin , and 32-fold less than that of ciprofloxacin .
The garenoxacin MIC at which 90% of isolates are inhibited ( MIC(90)s ; < or=0.008 microg / ml ) was at least 4-fold less than those of moxifloxacin and clindamycin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin for M. pneumoniae .
For Ureaplasma spp . , the garenoxacin MIC(90 ) ( 0.25 microg / ml ) was equivalent to those of moxifloxacin and doxycycline , 4-fold less than those of levofloxacin and sparfloxacin , 8-fold less than that of azithromycin , and 32-fold less than that of ciprofloxacin .
For M. hominis , the garenoxacin MIC(90 ) ( < or=0.008 microg / ml ) was 4-fold less than those of clindamycin and moxifloxacin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin .
The garenoxacin MIC at which 90% of isolates are inhibited ( MIC(90)s ; < or=0.008 microg / ml ) was at least 4-fold less than those of moxifloxacin and clindamycin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin for M. pneumoniae .
For M. hominis , the garenoxacin MIC(90 ) ( < or=0.008 microg / ml ) was 4-fold less than those of clindamycin and moxifloxacin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin .
For Ureaplasma spp . , the garenoxacin MIC(90 ) ( 0.25 microg / ml ) was equivalent to those of moxifloxacin and doxycycline , 4-fold less than those of levofloxacin and sparfloxacin , 8-fold less than that of azithromycin , and 32-fold less than that of ciprofloxacin .
The in vitro susceptibilities to garenoxacin ( BMS-284756 ) , an investigational des - fluoroquinolone , and eight other agents were determined for 63 Mycoplasma pneumoniae , 45 Mycoplasma hominis , 15 Mycoplasma fermentans , and 68 Ureaplasma sp . isolates .
The in vitro susceptibilities to garenoxacin ( BMS-284756 ) , an investigational des - fluoroquinolone , and eight other agents were determined for 63 Mycoplasma pneumoniae , 45 Mycoplasma hominis , 15 Mycoplasma fermentans , and 68 Ureaplasma sp . isolates .
The in vitro susceptibilities to garenoxacin ( BMS-284756 ) , an investigational des - fluoroquinolone , and eight other agents were determined for 63 Mycoplasma pneumoniae , 45 Mycoplasma hominis , 15 Mycoplasma fermentans , and 68 Ureaplasma sp . isolates .
The in vitro susceptibilities to garenoxacin ( BMS-284756 ) , an investigational des - fluoroquinolone , and eight other agents were determined for 63 Mycoplasma pneumoniae , 45 Mycoplasma hominis , 15 Mycoplasma fermentans , and 68 Ureaplasma sp . isolates .
Further study of garenoxacin is required , as it has great potential for use in the treatment of infections due to mycoplasmas and ureaplasmas .
In vitro susceptibilities to and bactericidal activities of garenoxacin ( BMS-284756 ) and other antimicrobial agents against human mycoplasmas and ureaplasmas .
PneumoniaMay be treated bysparfloxacin
The garenoxacin MIC at which 90% of isolates are inhibited ( MIC(90)s ; < or=0.008 microg / ml ) was at least 4-fold less than those of moxifloxacin and clindamycin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin for M. pneumoniae .
Further study of garenoxacin is required , as it has great potential for use in the treatment of infections due to mycoplasmas and ureaplasmas .
In vitro susceptibilities to and bactericidal activities of garenoxacin ( BMS-284756 ) and other antimicrobial agents against human mycoplasmas and ureaplasmas .
The in vitro susceptibilities to garenoxacin ( BMS-284756 ) , an investigational des - fluoroquinolone , and eight other agents were determined for 63 Mycoplasma pneumoniae , 45 Mycoplasma hominis , 15 Mycoplasma fermentans , and 68 Ureaplasma sp . isolates .
The in vitro susceptibilities to garenoxacin ( BMS-284756 ) , an investigational des - fluoroquinolone , and eight other agents were determined for 63 Mycoplasma pneumoniae , 45 Mycoplasma hominis , 15 Mycoplasma fermentans , and 68 Ureaplasma sp . isolates .
For M. hominis , the garenoxacin MIC(90 ) ( < or=0.008 microg / ml ) was 4-fold less than those of clindamycin and moxifloxacin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin .
The garenoxacin MIC at which 90% of isolates are inhibited ( MIC(90)s ; < or=0.008 microg / ml ) was at least 4-fold less than those of moxifloxacin and clindamycin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin for M. pneumoniae .
For Ureaplasma spp . , the garenoxacin MIC(90 ) ( 0.25 microg / ml ) was equivalent to those of moxifloxacin and doxycycline , 4-fold less than those of levofloxacin and sparfloxacin , 8-fold less than that of azithromycin , and 32-fold less than that of ciprofloxacin .
The garenoxacin MIC at which 90% of isolates are inhibited ( MIC(90)s ; < or=0.008 microg / ml ) was at least 4-fold less than those of moxifloxacin and clindamycin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin for M. pneumoniae .
For M. hominis , the garenoxacin MIC(90 ) ( < or=0.008 microg / ml ) was 4-fold less than those of clindamycin and moxifloxacin , 8-fold less than that of sparfloxacin , and 64-fold less than those of levofloxacin and ciprofloxacin .
For Ureaplasma spp . , the garenoxacin MIC(90 ) ( 0.25 microg / ml ) was equivalent to those of moxifloxacin and doxycycline , 4-fold less than those of levofloxacin and sparfloxacin , 8-fold less than that of azithromycin , and 32-fold less than that of ciprofloxacin .
Garenoxacin and the other fluoroquinolones tested were demonstrated to have bactericidal activities against M. pneumoniae and M. hominis by measurement of minimal bactericidal activities and by time - kill studies .
The in vitro susceptibilities to garenoxacin ( BMS-284756 ) , an investigational des - fluoroquinolone , and eight other agents were determined for 63 Mycoplasma pneumoniae , 45 Mycoplasma hominis , 15 Mycoplasma fermentans , and 68 Ureaplasma sp . isolates .
The in vitro susceptibilities to garenoxacin ( BMS-284756 ) , an investigational des - fluoroquinolone , and eight other agents were determined for 63 Mycoplasma pneumoniae , 45 Mycoplasma hominis , 15 Mycoplasma fermentans , and 68 Ureaplasma sp . isolates .
In vitro susceptibilities to and bactericidal activities of garenoxacin ( BMS-284756 ) and other antimicrobial agents against human mycoplasmas and ureaplasmas .
All Topics